Development of a level A in vitro-in vivo correlation for extended release dosage forms of quetiapine fumarate

Abstract

Quetiapine is an atypical antipsychotic recommended as first-line treatment for acute bipolar depression. The extended-release quetiapine formulation is intended to be administered as an once-daily dosing. The development of an in vitro-in vivo correlation (IVIVC) and the use of in vitro data to predict in vivo bioavailability parameters has been of great interest for the rational development and evaluation process for extended release dosage forms. The aim of this study was to develop an IVIVC for quetiapine extended release formulation. In vitro dissolution rate data were obtained using USP apparatus 2 at 50 rpm, in 3 bio-relevant dissolution media with different pH values (1.2, 4.5 and 6.8). The drug release profiles of the 2 extended release dosage forms were compared using the similarity factor (f ₂). The relative bioavailability of quetiapine was evaluated by a single-dose, randomized-sequence, open-label, 2 period cross over study with 16 healthy volunteers. A linear level A IVIVC model was established using percentage of absorbed and dissolved data obtained at pH 1.2. The developed IVIVC model was employed to predict quetiapine concentration-time profiles, as well as the bioequivalence parameters for test formulation. Percent prediction errors were estimated for C_max and AUC to evaluate the validity of the correlation. The values did not exceed 15%, proving the predictability of the correlation model. In conclusion, the established level A IVIVC model proved to be an excellent tool for predicting the rate and extent of quetiapine absorption as characterized by C_max and AUC for test formulation.

Key words

quetiapine - IVIVC - extended release - dissolution - bioavailability

• References

• 1 Gijsman HJ, Geddes JR, Rendell JM et al. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004; 161: 1537-1547
• 2 Taylor M, Mackay K, Shajahan P. Pharmacotherapy Update: Quetiapine use in Bipolar Disorder – What does the evidence tell us?. Clin Med Ther 2009; 1: 657-667
• 3 Suttajit S, Srisurapanont M, Maneeton N et al. Quetiapine for acute bipolar depression: a systematic review and meta-analysis. Drug Des Devel Ther 2014; 8: 827-838
• 4 Sanford M, Keating GM. Quetiapine: a review of its use in the management of bipolar depression. CNS Drugs 2012; 26: 435-460
• 5 McInyre A, Paisley D, Kouassi E et al. Quetiapine fumarate extended-release for the treatment of major depression with comorbid fibromyalgia syndrome: a double-blind, randomized, placebo-controlled study. Arthritis Rheumatol 2014; 66: 451-461
• 6 Thase ME. Quetiapine monotherapy for bipolar depression. Neuropsychiatr Dis Treat 2008; 4: 21-31
• 7 Jurdi RKA, Dixit LA, Sajatovic M. Role of extended release quetiapine in the management of bipolar disorders. Neuropsychiatr Dis Treat 2010; 6: 29-35
• 8 Baldwin CM, Scott LJ. Quetiapine extended release: in schizophrenia. CNS Drugs 2009; 23: 261-269
• 9 Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions and dosing. J Clin Psychiatry 2002; 63: 5-11
• 10 DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 2001; 40: 509-522
• 11 Estevez-Carrizo FE, Parrilo S, Ercoli MC et al. Single-dose relative bioavailability of a new quetiapine fumarate extended-release formulation: a postpradial, randomized, open-label, two-period crossover study in healthy Uruguayan volunteers. Clin Ther 2011; 33: 738-745
• 12 Yasir M, Asif M, Kumar A et al. Biopharmaceutical Classification System: An Account. Int J Pharm Tech Res 2010; 2: 1681-1690
• 13 Uppoor VRS. Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations. J Control Release 2001; 72: 127-132
• 14 Emami J. In vitro – In vivo correlation: from theory to applications. J Pharm Pharmaceut Sci 2006; 9: 31-51
• 15 Modi NB, Lam A, Lindemulder E et al. Application of in vitro – in vivo correlations (IVIVC) in setting formulation release specifications. Biopharm Drug Dispos 2000; 21: 321-326
• 16 FDA. Guidance for Industry. Bioanalytical Method Validation. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); USA: http://www.fda.gov/downloads/Drugs/Guidances/ucm070.107.pdf 2001
• 17 FDA. Guidance for Industry; Bioavailability and bioequivalence studies for orally administered drug products; General Considerations. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); USA: http://www.fda.gov/cder/guidance/5356fnl.pdf 2003
• 18 EMEA. Guideline on the Investigation of Bioequivalence. European Medicines Agency, Pre-authorization Evaluation of Medicines for Human Use, Committee for Medicinal Products for Human Use (CHMP); London, UK: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003011.pdf 2008
• 19 Gohel M, Delvadia R, Parikh D et al. Simplified mathematical approach for back calculation in Wagner-Nelson method: applications in in vitro and in vivo correlation (IVIVC) and formulation development work. Pharm Rev 2005; 3
• 20 FDA. Guidance for Industry; Extended release oral dosage forms: development, evaluation, and application of in vitro/in vivo correlations. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); USA: http://www.fda.gov/downloads/drugs/guidance/complianceregulatoryinformation/guidances/ucm070239.pdf 1997
• 21 Eddington ND, Marroum P, Uppoor R et al. Development and internal validation of an in vitro-in vivo correlation for a hydrophilic metoprolol tartrate extended release tablet formulation. Pharm Res 1998; 15: 466-473
• 22 Campos DR, Klein S, Zoller T et al. Evaluation of pantoprazole formulations in different dissolution apparatus using biorelevant medium. Arzneimittelforschung 2010; 60: 42-47
• 23 Rouini MR, Ardakani YH, Mirfazaelian A et al. Investigation on different levels of in vitro-in vivo correlation: gemfibrozil immediate release capsule. Biopharm Drug Dispos 2008; 29: 349-355